Literature DB >> 33598873

Prognostic factors for cytology-positive gastric cancer: a multicenter retrospective analysis.

Shunji Endo1, Kazuhiro Nishikawa2, Masakazu Ikenaga3, Kazumasa Fujitani4, Junji Kawada5, Tomoki Yamatsuji6, Hisako Kubota7, Masaharu Higashida7, Yoshinori Fujiwara7, Tomio Ueno7.   

Abstract

BACKGROUND: The prognosis of patients with gastric cancer and positive peritoneal lavage cytology is poor, even after gastrectomy. Though the standard therapy for this population is radical gastrectomy followed by S-1 chemotherapy, treatments vary among institutions and eras. We conducted a multicenter retrospective study to investigate the prognostic factors for cytology-positive gastric cancer.
METHODS: We reviewed the medical records obtained from 6 institutions, covering 2000-2019. There were 128 patients with positive cytology and no other distant metastases that underwent R1 gastrectomy. Univariate and multivariate analyses to identify prognostic factors for overall survival were conducted using Cox's proportional hazards models.
RESULTS: The median overall survival time was 18.6 months. In univariate analyses, age (≥ 80 years vs. < 70 years), performance status (2, 3 vs. 0), prognostic nutritional index (< 35 vs. ≥ 40), the extent of lymphadenectomy (D1 vs. ≥ D2), macroscopic type (type 4 vs. non-type 4), and postoperative chemotherapy (none vs. S-1) were significantly correlated with worse survival. Multivariate analysis revealed that lymph node metastasis (pN3b vs. pN0, hazard ratio 4.46, 95% confidence interval 1.17-16.9, p = 0.03) and postoperative chemotherapy (none vs. S-1, hazard ratio 2.28, 95% confidence interval 1.16-4.45, p = 0.02) were independent risk factors for death. No postoperative chemotherapy regimen showed a survival benefit over S-1 monotherapy.
CONCLUSIONS: Massive lymph node metastasis was an independent risk factor in cytology-positive gastric cancer. Postoperative chemotherapy was also an independent prognostic factor, though the most beneficial regimen was still uncertain.

Entities:  

Keywords:  Cell biology; Chemotherapy; Stomach neoplasms

Year:  2021        PMID: 33598873     DOI: 10.1007/s10147-021-01873-4

Source DB:  PubMed          Journal:  Int J Clin Oncol        ISSN: 1341-9625            Impact factor:   3.402


  2 in total

1.  Comparison of Neoadjuvant Chemotherapy to Surgery Followed by Adjuvant Chemotherapy in Japanese Patients with Peritoneal Lavage Cytology Positive for Gastric Carcinoma.

Authors:  Manabu Yamamoto; Hiroyuki Kawano; Shohei Yamaguchi; Akinori Egashira; Kazuhito Minami; Kenichi Taguchi; Yasuharu Ikeda; Masaru Morita; Yasushi Toh; Takeshi Okamura
Journal:  Anticancer Res       Date:  2015-09       Impact factor: 2.480

2.  Multicenter prospective trial of total gastrectomy versus proximal gastrectomy for upper third cT1 gastric cancer.

Authors:  Makoto Yamasaki; S Takiguchi; T Omori; M Hirao; H Imamura; K Fujitani; S Tamura; Y Akamaru; K Kishi; J Fujita; T Hirao; K Demura; J Matsuyama; A Takeno; C Ebisui; K Takachi; O Takayama; H Fukunaga; K Okada; S Adachi; S Fukuda; N Matsuura; T Saito; T Takahashi; Y Kurokawa; M Yano; H Eguchi; Y Doki
Journal:  Gastric Cancer       Date:  2020-10-29       Impact factor: 7.370

  2 in total
  2 in total

Review 1.  Role of Peritoneal Mesothelial Cells in the Progression of Peritoneal Metastases.

Authors:  Junliang Li; Tiankang Guo
Journal:  Cancers (Basel)       Date:  2022-06-09       Impact factor: 6.575

2.  hsa_circ_0060975 is highly expressed and predicts a poor prognosis in gastric cancer.

Authors:  Peng Xu; Xiaolan Xu; Lixiang Zhang; Zhengnan Li; Jianjun Qiang; Jie Yao; Aman Xu
Journal:  Oncol Lett       Date:  2021-06-24       Impact factor: 2.967

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.